Individualized diabetes care: Lessons from the real-world experience

Table 2 Landmark clinical trials with sodium-glucose cotransporter 2 inhibitor inhibitors and the efficacy on diabesity management

Study name	Year	Drug molecule	Mean weight reduction (95%CI)	Mean % reduction of HbA1c (95%CI)	Ref.
EMPA-REG Trial	2015	Empagliflozin 25 mg	-1.9 kg (-2.1 to -1.7)	-0.60 (-0.64 to -0.55)	[24]
CANVAS Trial	2017	Canagliflozin 300 mg	-2.8 kg (-3.21 to -2.39)	-0.80 (-0.62 to -0.98)	[25]
DECLARE-TIMI-58 Trial	2019	Dapagliflozin 10 mg	-1.51 kg (-1.81 to -1.21)	-0.55 (-0.62 to -0.53)	[26]

HbA1c: Glycated hemoglobin; CI: Confidence interval.